1. European Medicines Agency. Tygacil®. European Medicines Agency, 2015. https://www.ema.europe.eu/docs/en/documents/overview/tygacil-epar-summary-public_en.pdf. Accessed Dec 2019.
2. Food and Drugs Administration. Tygacil®. FDA, 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf. Accessed Dec 2019.
3. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis–authors' responses. J Antimicrob Chemother. 2011;66(12):2895–6.
4. Falagas M, Vardakas K, Tsiveriotis K, Triarides N, Tansarli G. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1–7.
5. Food and Drugs Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. FDA, 2010. https://www.fda.gov/Drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics. Accessed Dec 2019.